news
ClassPass expands into wellness experiences, FDA reviews BPC-157
ClassPass is pushing into self-care and experiences, moving beyond just fitness classes. Meanwhile, the FDA is meeting to assess regulatory changes for peptides like BPC-157, and Neko Health just secured $700 million Series C funding ahead of its US launch.
ClassPass is pushing into self-care and experiences, moving beyond just fitness classes. Meanwhile, the FDA is meeting to assess regulatory changes for peptides like BPC-157, and Neko Health just secured $700 million Series C funding ahead of its US launch.
The architecture take
ClassPass is still trying to figure out what it wants to be when it grows up, shifting from just workout bookings to 'experiences.' This tells you a lot about the actual stress response a normal person is trying to solve: it's not just about lifting weights; it's about chilling out, too. The FDA review of peptides like BPC-157 is the real headliner here. Expect regulators to start drawing some hard lines around what's available and how, which could reshape access to non-GLP-1 longevity tools. That Neko Health (chronic disease early detection clinic) just bagged $700 million and is eyeing the US is the clearest signal yet that biological age tracking and personalized preventative health are moving from niche obsession to mainstream, insurance-friendly healthcare. Watch for more clinics to follow their lead with biomarker-driven diagnostics.